PetVivo Holdings, Inc. Announces Participation in The Microcap Conference 2025
PetVivo Holdings (OTCQB:PETV) has announced its participation in The Microcap Conference 2025, scheduled for January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. CEO John Lai will present a company overview and discuss their lead product, SPRYNG™ with OsteoCushion™ Technology.
SPRYNG is an intra-articular injectable veterinary medical device using sterilized, extra-cellular matrix microparticles. The product works by adsorbing onto animals' joint synovial lining and integrating with subsynovial tissue, helping restore proper joint mechanics and manage conditions like joint instability, degenerative joint disease, and osteoarthritis.
PetVivo Holdings (OTCQB:PETV) ha annunciato la sua partecipazione alla Microcap Conference 2025, in programma dal 28 al 30 gennaio 2025, presso il Borgata Hotel Spa & Casino ad Atlantic City, NJ. L'amministratore delegato John Lai presenterà una panoramica dell'azienda e discuterà del loro prodotto di punta, SPRYNG™ con Tecnologia OsteoCushion™.
SPRYNG è un dispositivo medico veterinario iniettabile intra-articolare che utilizza microparticelle di matrice extracellulare sterilizzate. Il prodotto funziona adsorbendo sulla membrana sinoviale delle articolazioni degli animali e integrandosi con il tessuto subsinoviale, contribuendo a ripristinare la corretta meccanica articolare e gestire condizioni come l'instabilità articolare, la malattia articolare degenerativa e l'osteoartrite.
PetVivo Holdings (OTCQB:PETV) ha anunciado su participación en La Conferencia Microcap 2025, programada del 28 al 30 de enero de 2025, en el Borgata Hotel Spa & Casino en Atlantic City, NJ. El CEO John Lai presentará una visión general de la empresa y discutirá su producto principal, SPRYNG™ con Tecnología OsteoCushion™.
SPRYNG es un dispositivo médico veterinario injectable intraarticular que utiliza micropartículas de matriz extracelular esterilizadas. El producto funciona al adsorberse en el revestimiento sinovial de las articulaciones de los animales e integrarse con el tejido subsinovial, ayudando a restaurar la mecánica articular adecuada y a manejar condiciones como la inestabilidad articular, la enfermedad articular degenerativa y la osteoartritis.
PetVivo Holdings (OTCQB:PETV)는 2025년 1월 28일부터 30일까지 뉴저지 애틀랜틱 시티의 Borgata Hotel Spa & Casino에서 열리는 Microcap Conference 2025에 참여한다고 발표했습니다. CEO John Lai는 회사 개요를 발표하고 그들의 주요 제품인 SPRYNG™와 OsteoCushion™ 기술에 대해 논의할 것입니다.
SPRYNG은 멸균된 세포외 기질 미세입자를 사용하는 관절 내 주사 가능한 수의학 의료 기기입니다. 이 제품은 동물의 관절 활막에 흡착되어 피하 활막 조직과 통합되며, 적절한 관절 역학을 복원하고 관절 불안정성, 퇴행성 관절 질환 및 골관절염과 같은 상태를 관리하는 데 도움을 줍니다.
PetVivo Holdings (OTCQB:PETV) a annoncé sa participation à la Microcap Conference 2025, prévue du 28 au 30 janvier 2025 au Borgata Hotel Spa & Casino à Atlantic City, NJ. Le PDG John Lai présentera un aperçu de l'entreprise et discutera de leur produit phare, SPRYNG™ avec Technologie OsteoCushion™.
SPRYNG est un dispositif médical vétérinaire injectable intra-articulaire utilisant des microparticules de matrice extracellulaire stérilisées. Le produit fonctionne en s'adsorbant sur le revêtement synovial des articulations des animaux et en s'intégrant avec le tissu subsynovial, aidant à restaurer la mécanique articulaire appropriée et à gérer des conditions telles que l'instabilité articulaire, la maladie articulaire dégénérative et l'arthrose.
PetVivo Holdings (OTCQB:PETV) hat seine Teilnahme an der Microcap Conference 2025 angekündigt, die vom 28. bis 30. Januar 2025 im Borgata Hotel Spa & Casino in Atlantic City, NJ, stattfinden wird. CEO John Lai wird einen Unternehmensüberblick präsentieren und über ihr Hauptprodukt, SPRYNG™ mit OsteoCushion™ Technologie, sprechen.
SPRYNG ist ein intraartikuläres injizierbares veterinärmedizinisches Gerät, das sterilisierten extrazellulären Matrixmikropartikeln verwendet. Das Produkt adsorbiert an der synovialen Auskleidung der Gelenke von Tieren und integriert sich mit dem subsynovialen Gewebe, wodurch es hilft, die richtige Gelenkmechanik wiederherzustellen und Zustände wie Gelenkinstabilität, degenerative Gelenkerkrankungen und Arthrose zu behandeln.
- None.
- None.
MINNEAPOLIS, MN / ACCESSWIRE / December 19, 2024 / PetVivo Holdings, Inc. (OTCQB:PETV, PETVW), a leading provider of medical devices and biomedical therapeutics for equines and companion animals, is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.
John Lai, Chief Executive Officer of PetVivo Holdings, Inc. will provide a Company overview as well as discuss its lead product, SPRYNG™ with OsteoCushion™ Technology. Spryng is an intra-articular injectable veterinary medical device composed of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal's subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.
The 2025 event will feature:
Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB:PETV, PETVW) is a biomedical device company focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The company is pursuing a strategy of developing and commercializing human therapies for the treatment of companion animals in capital and time efficient ways. A key component of this strategy is an accelerated timeline to revenues for veterinary medical devices that can enter the market much earlier than more stringently regulated human pharmaceuticals and biologics.
PetVivo has developed a robust pipeline of products for the medical treatment of animals and people, with a portfolio of 21 patents that protect the company's biomaterials, products, production processes and methods of use. The company's commercially launched flagship product, Spryng™ with OsteoCushion™ Technology, is a veterinarian-administered, intra-articular injectable designed for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses.
For more information about PetVivo and its revolutionary Spryng with OsteoCushion Technology, email info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the company's Investor Relations website, in addition to following the company's press releases, SEC filings, public conference calls, presentations and webcasts.
Forward-Looking commercial Statements
The foregoing information regarding PetVivo Holdings, Inc. (the "Company") may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company's proposed development and commercial timelines, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company's business are described in detail in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216
SOURCE: PetVivo Holdings, Inc.
View the original press release on accesswire.com
FAQ
When and where is PetVivo Holdings (PETV) presenting at The Microcap Conference 2025?
What is PETV's SPRYNG technology used for in veterinary medicine?
How does PetVivo's SPRYNG technology work in animal joints?
What medical conditions can PETV's SPRYNG technology treat in animals?
